Pharmacokinetic interaction study between quercetin and valsartan in rats and in vitro models

Drug Development and Industrial Pharmacy

Volumn 39, Issue 6, 2013, Pages 865-872

  Challa, Venkatesh R ^a   Ravindra Babu, P ^b   Challa, Siva R ^b   Johnson, Benito ^a   Maheswari, C ^a  

^a RVS College of Pharmaceutical Sciences   (India)

^b KVSR SIDDHARTHA COLLEGE OF PHARMACEUTICAL SCIENCES   (India)

Author keywords

Cardioprotective; CYP3A4; P glycoprotein; Pharmacokinetics; Quercetin

Indexed keywords

QUERCETIN; VALSARTAN; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIOXIDANTS; DRUG INTERACTIONS; INTESTINAL ABSORPTION; MALE; ORGAN CULTURE TECHNIQUES; QUERCETIN; RANDOM ALLOCATION; RATS; RATS, WISTAR; TETRAZOLES; VALINE;

EID: 84877034928     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.693502     Document Type: Article

References (24)

1. Gottlieb S. (1999). Antihistamine drug withdrawn by manufacturer. BMJ, 319:7.
2. Furberg CD, Pitt B. (2001). Withdrawal of cerivastatin form the world market. Curr Control Trials Cardiovasc Med, 2:2005-2007.
3. Marwick C. (2003). Bayer is forced to release documents over withdrawal of cerivastatin. BMJ, 326:518.
4. Huang SM, Hall SD, Watkins P, Love LA, Serabjit-Singh C, Betz JM et al.; Center for Drug Evaluation and Research and Office of Regulatory Affairs, Food and Drug Administration, Rockville, MD, USA. (2004). Drug interactions with herbal products and grapefruit juice: a conference report. Clin Pharmacol Ther, 75:1-12.
5. Flesch G, Muller P, Lloyd P. (1997). Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol, 52:115-120.
6. Abdul Ahad, Mohammed Aqil, Kanchan Kohli, Yasmin Sultana, Mohd Mujeeb, Asgar Ali. (2011). Role of novel terpenes in transcutaneous permeation of valsartan: effectiveness and mechanism of action. Drug Dev Ind Pharm,37:583-596.
7. Herbert JM, Delisee C, Dol F, Schaeffer P, Cazaubon C, Nisato D et al. (1994). Effect of SR 47436, a novel angiotensin II AT1 receptor antagonist, on human vascular smooth muscle cells in vitro. Eur J Pharmacol, 251:143-150.
8. de Groot H. (1994). Reactive oxygen species in tissue injury. Hepatogastroenterology, 41:328-332.
9. Havsteen B. (1983). Flavonoids, a class of natural products of high pharmacological potency. Biochem Pharmacol, 32:1141-1148.
10. Scambia G, Raneletti FO, Panici PB, Bonanno G, De Vincenzo R, Ferrandina G, Maggiano N, Capelli A, Mancuso S. (1992). Inhibitory effects of quercetin on primary ovarian and endometrial cancers and synergistic activity with cis-diaminedichloroplatinum (II). Gynecol Oncology, 45:13-19.
11. Kaul RN, Middleton E Jr, Ogra PL. (1985). Antiviral effect of flavonoids on human viruses. J Med Virol, 15:71-79.
12. Mizui T, Sato H, Hirose F, Doteuchi M. (1987). Effect of antiperoxidative drugs on gastric damage induced by ethanol in rats. Life Sci, 41:755-763.
13. Singh D, Chander V, Chopra K. (2004). Quercetin, a bioflavonoid, attenuates ferric nitrilotriacetate-induced oxidative renal injury in rats. Drug Chem Toxicol, 27:145-156.
14. Cheong H, Ryu SY, Kim KM. (1999). Anti-allergic action of resveratrol and related hydroxystilbenes. Planta Med, 65: 266-268.
15. Omer C, Mehmet K, Ahmet Sukru O. (2005). Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and beta cell damage in rat pancreas. Pharmacol Res, 51:117-123.
16. Marcus AJ, Safier LB. (1993). Thromboregulation: multicellular modulation of platelet reactivity in hemostasis and thrombosis. FASEB J, 7:516-522.
17. Shoskes DA. (1998). Effect of bioflavonoids quercetin and curcumin on ischemic renal injury: a new class of renoprotective agents. Transplantation, 66:147-152.
18. Vicentini FT, Vaz MM, Fonseca YM, Bentley MV, Fonseca MJ. (2011). Characterization and stability study of a water-in-oil microemulsion incorporating quercetin. Drug Dev Ind Pharm, 37:47-55.
19. Augustijns PF, Bradshaw TP, Gan LS, Hendren RW, Thakker DR. (1993). Evidence for a polarized efflux system in CACO-2 cells capable of modulating cyclosporin A transport. Biochem Biophys Res Commun, 197:360-365.
20. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK et al. (1997). Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA, 94:2031-2035.
21. Huang J, Kwong J, Sun EC, Liang TJ. (1996). Proteasome complex as a potential cellular target of hepatitis B virus X protein. J Virol, 70:5582-5591.
22. Krishna R, Mayer LD. (2000). Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci, 11:265-283.
23. Meerum Terwogt JM, Malingre MM, Beijnen JH, ten Bokkel Huinink WW, Rosing H, Koopman FJ et al. (1999). Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res, 5:3379-3384.
24. Hochman JH, Chiba M, Yamazaki M, Tang C, Lin JH. (2001). P-glycoprotein-mediated efflux of indinavir metabolites in Caco-2 cells expressing cytochrome P450 3A4. J Pharmacol Exp Ther, 298:323-330.